Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain

Hair loss occurs commonly as a result of radiotherapy administered to the brain, and this can contribute to the distress and social isolation of patients with advanced cancer. In this study a topical gel will be applied directly to the scalp during each dose of radiotherapy. The goal is to determine to what extent the experimental drug is successful in lessening the hair loss.

Additional locations may be listed on ClinicalTrials.gov for NCT00801086.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase II

Trial Typeprevention

Lead OrganizationMitos Pharmaceuticals

• Primary IDMITO 02-03
• Secondary IDsNCI-2012-00422
• ClinicalTrials.gov IDNCT00801086